Cargando…
Therapeutic strategies for afatinib‐resistant lung cancer harboring HER2 alterations
Human epidermal growth factor receptor 2 (HER2) plays an important role in the pathogenesis of various cancers. HER2 alterations have been suggested to be a therapeutic target in non‐small‐cell lung cancer (NSCLC), just as in breast and gastric cancers. We previously reported that the pan‐HER inhibi...
Autores principales: | Torigoe, Hidejiro, Shien, Kazuhiko, Takeda, Tatsuaki, Yoshioka, Takahiro, Namba, Kei, Sato, Hiroki, Suzawa, Ken, Yamamoto, Hiromasa, Soh, Junichi, Sakaguchi, Masakiyo, Tomida, Shuta, Tsukuda, Kazunori, Miyoshi, Shinichiro, Toyooka, Shinichi |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5980184/ https://www.ncbi.nlm.nih.gov/pubmed/29532558 http://dx.doi.org/10.1111/cas.13571 |
Ejemplares similares
-
Anti-tumor effect of neratinib against lung cancer cells harboring HER2 oncogene alterations
por: Ogoshi, Yusuke, et al.
Publicado: (2019) -
Antitumor effect of afatinib, as a human epidermal growth factor receptor 2‐targeted therapy, in lung cancers harboring HER2 oncogene alterations
por: Suzawa, Ken, et al.
Publicado: (2015) -
Targeting the miR-200c/LIN28B axis in acquired EGFR-TKI resistance non-small cell lung cancer cells harboring EMT features
por: Sato, Hiroki, et al.
Publicado: (2017) -
Acquired resistance mechanisms to afatinib in HER2‐amplified gastric cancer cells
por: Yoshioka, Takahiro, et al.
Publicado: (2019) -
Therapeutic potential of targeting S100A11 in malignant pleural mesothelioma
por: Sato, Hiroki, et al.
Publicado: (2018)